| Name | Title | Contact Details |
|---|
Horton and Converse Pharmacies is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merck-Medco is a Franklin Lakes, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.
(877) 663-7674
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.